â– PHYSIOLOGICAL CORE: SIADH is characterized by continuous, unregulated release of Antidiuretic Hormone (ADH) from either the posterior pituitary or ectopic sources, independent of plasma osmolarity or volume status.
â– EUVOLEMIC HYPONATREMIA MECHANISMS:
1. Excessive Water Reabsorption: High ADH activates V2 receptors, inserting Aquaporin-2 channels in the collecting duct.
2. Volume Expansion: This causes excessive free water retention, expanding both intracellular and extracellular fluid volumes.
3. Renin & Aldosterone Suppression: This mild volume expansion stimulates ANP release and suppresses the renin-angiotensin-aldosterone system.
4. Natriuresis Promotion: Renin suppression promotes renal sodium excretion (natriuresis), keeping the patient clinically euvolemic while worsening hyponatremia.
â– TOXICOLOGICAL OVERDOSAGE PROTOCOL:
Toxic absorption or cumulative exposure results in receptor saturation, chemical cell damage, or severe secondary target-organ failure. Immediate toxicological profiles dictate serum or urine screens.
â– SYSTEMIC HOMEOSTATIC REMODELING:
Prolonged pathologic strain causes adjacent cardiovascular, renal, or endocrine systems to remodel dynamically to maintain overall tissue perfusion.
[HY-BOARD-1299]
🌟 Dynamic Clinical Key:
SIADH can be triggered by small cell lung carcinoma, CNS disorders, or drugs (SSRIs). It presents with hyponatremia (<135 mEq/L) and highly concentrated urine (>100 mOsm/L). Treatment includes fluid restriction, hypertonic saline (for severe, symptomatic hyponatremia), or ADH receptor antagonists (vaptans). Administer physiological antidotes and active elimination therapies (activated charcoal or hemodialysis) without delay. Intercept compensatory loops early before they turn into independent pathologic drivers.